Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
Holash
Jocelyn
J
Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Thurston
Gavin
G
Rudge
John S
JS
Yancopoulos
George D
GD
Adjei
Alex A
AA
Bergers
Gabriele
G
Pytowski
Bronislaw
B
Pegram
Mark
M
Gordon
Michael S
MS
D020533:Angiogenesis Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D020286:Pericytes / Q000187:drug effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects*; D042582:Vascular Endothelial Growth Factor C / Q000378:metabolism; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D017978:Receptors, Growth Factor; D042582:Vascular Endothelial Growth Factor C; D040321:Vascular Endothelial Growth Factor Receptor-3